On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...
26d
H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on ACLX stock, giving a Buy rating today.Pick the best stocks and ...
Below is Validea's guru fundamental report for ARCELLX INC (ACLX). Of the 22 guru strategies we follow, ACLX rates highest using our P/B Growth Investor model based on the published strategy of ...
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients Arcellx's Phase 2 trial of anito-cel in relapsed multiple ...
In a report released today, George Farmer from Scotiabank maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price target of $82.00. The company’s shares closed yesterday ...
REDWOOD CITY, Calif., November 07, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback